Karyopharm Therapeutics (KPTI) Misses Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip rally offsets renewed Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices slide over 1% as US-Iran conflict clouds Hormuz reopening
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Karyopharm Therapeutics (KPTI) Initiates Selinexor Phase 2 in SIRRT Patients
November 10, 2014 7:22 AM ESTKaryopharm Therapeutics (Nasdaq: KPTI) announced the initiation of its Phase 2 study of Selinexor (KPT-330) in patients with Richter's transformation (SIRRT) that is relapsed after or refractory to chemotherapy. This multi-center study of Selinexor, one of the company's novel, oral Selective Inhibitor of Nuclear Export / SINE compounds, will enroll approximately 50 patients in approximately 35 sites worldwide.
This single arm, open-label, Phase 2 study will... More
